NCT05438212

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-10-24Est. Completion: 2027-03-16

Enrollment target: 237 participants

Locations

Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Kaiser Permanente-Anaheim, Anaheim, California, United States
Sutter Auburn Faith Hospital, Auburn, California, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
Kaiser Permanente-Bellflower, Bellflower, California, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Memorial Medical Center, Modesto, California, United States
Kaiser Permanente-Ontario, Ontario, California, United States
Saint Joseph Hospital - Orange, Orange, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Other microbiome trials you might be interested in

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Recruiting

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatm…

Anchorage, United StatesEst. completion Dec 31, 2026

View Trial →

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Phase 3Recruiting

Advanced Non-small Cell Lung Cancer, HER2 Mutation

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.